COVID-19 Global Updates & Resources

Toulouse University Hospital is a conducting a pharmacoepidemiological study designed to look at all adult ITP patient’s who are treated for their persistent (≥3 months) primary ITP in France to assess the clinical benefit-to-risk ratio of available second-line therapies. Participants will be recruited using the French Health Insurance System (SNIIRAM) database which covers the entire French population. Participants must be over the age of 18 years. They must also be registered in the database between 2009-2012.

France

https://www.clinicaltrials.gov/ct2/show/NCT03429660?recrs=ab&cond=Immune+Thrombocytopenia&draw=2&rank=37

Recruiting